ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner

Huang, Si-cong; Chen, Yi-mei; Hu, Ying-yu; Shi, Yong-jie; Xiao, Qi-wen; Li, Zhe; Kang, Jia-le; Zhou, Qiang; Shen, Gang*; Jia, Hong-yun*广州医学院; 广州中医药大学; 南方医科大学
DISEASE MARKERS2022-10-25DOI: 10.1155/2022/6138941
3被引10阅读
引用收藏
分享

摘要

Backgound. Multiple patients with hepatocellular carcinoma (HCC) received sorafenib therapy presented primary or secondary chemoresistance. The underlying mechanisms of chemoresistance are rather vague, ferroptosis is a new kind of cell death, and its discovery provides new opportunities to overcome sorafenib resistance. Therefore, it is essential to investigate the regulators of ferroptosis and implement a corresponding therapy strategy. Methods and Results. The levels of MCF2L were detected by PCR and western blotting assay. The effect of MCF2L on ferroptosis was confirmed by MTT, colony formation assay, Brdu, in vivo animal experiment, and the content of Iron, GSH, ROS, and MDA. The underlying mechanisms were explored by PCR, western blotting, and affinity precipitation assay. Our findings demonstrated that MCF2L is remarkedly upregulated in HCC tissues, and sorafenib can induce the levels of MCF2L, suggesting that MCF2L might function in sorafenib resistance of HCC. Further analysis showed that downregulation of MCF2L enhances HCC cell death induced by sorafenib, and ferroptosis inhibitor can reverse this process. Subsequent experiments showed that downregulation of MCF2L elevates the content of Iron, ROS, and MDA, which are all indicators of ferroptosis. Finally, mechanism analysis showed that MCF2L regulates the PI3K/AKT pathway in a RhoA/Rac1 dependent manner. Conclusions. Our study showed that targeting MCF2L may be a hopeful method to overcome sorafenib-resistance through inducing ferroptosis in HCC.

学科与关键词

关键词
SORAFENIB RESISTANCEMECHANISMSDEATHINHIBITIONIRONPI3K
相关
加载中…
  • ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
    Huang, Wenbin; Chen, Kunling; Lu, Yishi; Zhang, Donghui; Cheng, Yuan; Li, Liuran; Huang, Weimei; He, Guolin; Liao, Hangyu; Cai, Lei; Tang, Yujun; Zhao, Liang*; Pan, MingxinNeoplasia, 2021, 23(12): 1227-1239.被引 59
  • CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells
    Li, Hui; Zhao, Juan*; Zhong, Xiao-lan; Xu, Pei-yan; Du, Li-jun; Fang, Ping; Tan, Li-juan; Li, Mei-juan; Zhang, Cheng-fang; Cao, Tian-sheng*Applied Biochemistry and Biotechnology - Part A Enzyme Engineering and Biotechnology, 2023, 195(1): 597-609.被引 8
  • FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma
    Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
DISEASE MARKERS
发表日期
2022-10-25
卷期
第 2022 卷
页码
6138941
DOI
10.1155/2022/6138941
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Guangdong Medical Science and Technology Research Fund Project; Guangzhou Health Science and Technology Project; National Natural Science Foundation of China; Natural Science Foundation of Guangdong; [A2021053]; [A2019189]; [2019A010057]; [20211A011079]; [82004459]; [2018A030310521]

作者

  • H

    Huang, Si-cong (第一作者)

    2 · guangzhou med univ

  • C

    Chen, Yi-mei

    2 · guangzhou med univ

查看全部 10 位作者收起作者
  • H

    Hu, Ying-yu

    southern med univ

  • S

    Shi, Yong-jie

    2 · guangzhou med univ

  • X

    Xiao, Qi-wen

    2 · guangzhou med univ

  • L

    Li, Zhe

    2 · guangzhou univ chinese med

  • K

    Kang, Jia-le

    2 · guangzhou med univ

  • Z

    Zhou, Qiang

    2 · guangzhou med univ

  • S

    Shen, Gang (通讯)

    capital inst pediat

  • J

    Jia, Hong-yun (通讯)

    2 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417